Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
PaperCitations, authors & open-access status
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 187 citations, 2021 year and hybrid oa status.
187
Citations
2021
Year
hybrid
OA Status